GIANT BIOGENE(02367.HK): Cross-linked Recombinant Collagen Implant Obtains NMPA Medical Device Registration Certificate, World’s First Filler Indicated for Neck Wrinkle Correction
NewTimeSpace News: On 17 June 2026, Giant Biogene Holding Co., Ltd. (02367.HK) released a voluntary announcement, disclosing that Shaanxi Giant Biotech Co., Ltd., its wholly-owned subsidiary, has obtained the Medical Device Registration Certificate for Cross-linked Recombinant Collagen Implant (Registration No.: Guo Xie Zhu Zhun 20263131219) issued by NMPA.
The product adopts the full-length sequence of mature human Type III collagen consisting of 1,068 amino acids, fully retaining the native functional domains of collagen. It is manufactured via a physical cross-linking process free of residual chemical cross-linking agent risks, and is intended for intradermal injection into the dermal layer of the neck to improve moderate and severe horizontal neck wrinkles.
- GIANT BIOGENE(02367.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 939.71 million, YoY decrease of 20.5%
- GIANT BIOGENE(02367.HK) closed 7.89% higher, The full-day turnover stood at HKD 541.86 million
- GIANT BIOGENE(02367.HK) will spend HKD 13.76 million to repurchase 400 thousand shares on Jan 9, 2026
